This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Conversation on the Chronic Urticaria Landscape

Ticker(s): CLDX, NVS, RHHBF

Who's the expert?

Institution: University of Rochester

  • Professor of Dermatology, Professor of Medicine (AIR) and Pathology & Laboratory Medicine at University of Rochester Medical Center.
  • Manages 500 patients with atopic dermatitis (60% Pediatric) and 30 patients per month with chronic urticaria.
  • Research was instrumental in the development of dupilumab (Dupixent); Lead author of a 2014 NEJM paper that set the stage for the FDA approval of Dupixent.

Interview Questions

Please tell us about your clinical experience. How many patients with dermatological issues do you treat on a yearly basis, what is the typical therapy choice for chronic urticaria patients?

Added By: userc97bddfc

Walk us through your treatment algorithm. How many patients move onto biologics?

Added By: userc97bddfc

How likely would you be to use Ligelizumab (QGE031) in your patients? Will this majorly disrupt usage of Xolair?

Added By: userc97bddfc

Where does a therapy like CDX-0159 fit into the current paradigm?

Added By: userc97bddfc

Any other exciting modalitis? Do you view BTKs as a real threat or is the tolerability going to be a major question?

Added By: userc97bddfc

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.